论文部分内容阅读
目的探讨抗癫痫新药单药或联合用药对癫痫患儿血液系统指标的影响。方法观察并分析广东省人民医院2008年6月-2014年12月收治的70例癫痫患儿在抗癫痫新药单药或联合用药至少1年后血白细胞、血小板、血红蛋白含量的变化,以同期门诊20例健康体检儿童作为对照组。结果奥卡西平联合拉莫三嗪治疗癫痫患儿6个月及12个月均引起白细胞及血小板计数显著降低,与对照组相比差异有统计学意义(P<0.05);奥卡西平联合左乙拉西坦治疗癫痫患儿6个月白细胞计数明显降低,与对照组比较差异有统计学意义(P<0.05);左乙拉西坦联合托吡酯治疗癫痫患儿12个月白细胞计数明显降低,与对照组比较差异有统计学意义(P<0.05);其他联合用药或单用抗癫痫新药对血液系统指标无明显影响(P>0.05)。结论奥卡西平联合拉莫三嗪会引起癫痫患儿白细胞及血小板计数降低,奥卡西平联合左乙拉西坦及左乙拉西坦联合托吡酯治疗会引起癫痫患儿白细胞计数降低;其他抗癫痫新药联合用药或单用抗癫痫新药对血液系统指标无明显影响。
Objective To investigate the influence of single antiepileptic drug or combination therapy on hematological system in children with epilepsy. Methods The changes of leukocyte, platelet and hemoglobin levels in 70 children with epilepsy admitted to Guangdong Provincial People’s Hospital from June 2008 to December 2014 at least one year after anti-epileptic drug monotherapy or combination therapy were observed. Twenty healthy children as control group. Results Both oxcarbazepine and lamotrigine in children with epilepsy at 6 months and 12 months caused a significant decrease in leukocyte and platelet counts, which was significantly different from the control group (P <0.05) Levocitin in children with epilepsy at 6 months significantly reduced white blood cell count, compared with the control group, the difference was statistically significant (P <0.05); levetiracetam combined with topiramate in children with epilepsy at 12 months, white blood cell count was significantly lower, Compared with the control group, the difference was statistically significant (P <0.05); other combination drugs or anti-epileptic drugs alone had no significant effect on the blood system parameters (P> 0.05). Conclusions Oxalicarb combined with lamotrigine can reduce leucocyte and platelet count in children with epilepsy. Oxcarbazepine combined with levetiracetam and levetiracetam combined with topiramate can reduce the white blood cell count in children with epilepsy. Other antiepileptic New drug combination therapy or anti-epilepsy drugs alone had no significant effect on blood system parameters.